Atsunori Kashiwagi
Overview
Explore the profile of Atsunori Kashiwagi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
307
Citations
8188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamamoto Y, Sekine O, Ito-Kobayashi J, Nishida A, Togawa T, Ozamoto Y, et al.
J Diabetes Investig
. 2024 Nov;
16(2):343-347.
PMID: 39556486
We report case details of a morbidly obese patient with type 2 diabetes mellitus (T2DM) who became a failure of diabetes remission after laparoscopic sleeve gastrectomy (LSG). He had a...
2.
Kashiwagi A, Shoji S, Kosakai Y, Yoshinaga Y, Rokuda M
J Diabetes Investig
. 2023 Dec;
15(3):374-387.
PMID: 38112598
Aims/introduction: Healthcare resource utilization (HCRU) and healthcare costs are important factors to consider when selecting appropriate treatment for type 2 diabetes mellitus. We compared the HCRU and healthcare costs of...
3.
Yamamoto Y, Togawa T, Sekine O, Ozamoto Y, Fuse J, Azuma C, et al.
Endocr J
. 2023 Oct;
70(12):1141-1157.
PMID: 37853621
To determine the normalization of postprandial blood glucose (PG) and triglyceride (TG) excursions in 30 morbidly obese patients with or without diabetes mellitus (DM) 1-year after they underwent a laparoscopic...
4.
Kobayashi M, Maruyama N, Yamamoto Y, Togawa T, Ida T, Yoshida M, et al.
J Diabetes Investig
. 2023 Feb;
14(5):648-658.
PMID: 36729958
Aims/introduction: Glucagon, a peptide hormone produced from proglucagon, is involved in the pathophysiology of diabetes. Plasma glucagon levels are currently measured by sandwich enzyme-linked immunosorbent assay (ELISA), but the currently...
5.
Kashiwagi A, Shoji S, Kosakai Y, Koga T, Asakawa K, Rokuda M
J Diabetes Investig
. 2022 Dec;
14(3):404-416.
PMID: 36515129
Aims/introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown beneficial effects on cardiometabolic risk factors (hemoglobin A1c, body mass index, systolic blood pressure) in patients with type 2 diabetes mellitus. We...
6.
Kashiwagi A, Shoji S, Onozawa S, Kosakai Y, Waratani M, Ito Y
J Diabetes Investig
. 2022 Mar;
13(7):1175-1189.
PMID: 35243799
Aims/introduction: To evaluate the benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) versus dipeptidyl peptidase-4 inhibitors (DPP4i) in reducing cardiovascular disease (CVD) events in patients with type 2 diabetes mellitus with...
7.
Yamamoto Y, Ozamoto Y, Kobayashi M, Tezuka Y, Azuma C, Sekine O, et al.
Endocr J
. 2022 Jan;
69(6):689-703.
PMID: 35082201
A new meal tolerance test (MTT) using a 75 g glucose- and high fat-containing meal was applied to classify glucose intolerance in morbidly obese patients. According to the MTT data,...
8.
Kashiwagi Y, Aburaya S, Sugiyama N, Narukawa Y, Sakamoto Y, Takahashi M, et al.
Sci Rep
. 2021 Oct;
11(1):20016.
PMID: 34608253
No abstract available.
9.
Kashiwagi Y, Aburaya S, Sugiyama N, Narukawa Y, Sakamoto Y, Takahashi M, et al.
Sci Rep
. 2021 Sep;
11(1):18398.
PMID: 34526589
Periodontal infection induces systemic inflammation; therefore, aggravating diabetes. Orally administered periodontal pathogens may directly alter the gut microbiota. We orally treated obese db/db diabetes mice using Porphyromonas gingivalis (Pg). We...
10.
Tezuka Y, Sekine O, Hirano A, Hanada Y, Nakanishi I, Ariga M, et al.
Diabetes Ther
. 2020 Oct;
12(1):431-440.
PMID: 33108650
Introduction: Various types of skin lesions with pruritus have been reported in participants of Asian clinical trials on sodium-glucose cotransporter-2 (SGLT2) inhibitors. The aim of this study was to determine...